By SPEAKIN’ OUT NEWS
Could a medicine best known for weight loss eventually help lower a woman’s risk of breast cancer? New research is raising that possibility — but doctors are not yet calling Wegovy a cancer-prevention drug.
A 2026 study published in JCO Oncology Practice reviewed more than 111,000 women ages 45 to 80 with overweight or obesity who underwent breast imaging. Researchers found that women who had used GLP-1 medicines had about a 30 percent lower incidence of breast cancer than comparable women who had not used them.
That is encouraging, but it does not prove Wegovy itself prevents breast cancer. Wegovy contains semaglutide and belongs to the GLP-1 class examined in the study. Because the research was observational, scientists say prospective clinical trials are still needed to determine whether the medications directly reduce cancer risk.
One possible explanation is weight loss. The American Cancer Society says excess body weight after menopause increases breast cancer risk, in part because fat tissue can raise estrogen levels and is associated with higher insulin levels.
For Black women, the question carries added urgency. The American Cancer Society reports that Black women have a higher breast cancer death rate than White women despite slightly lower incidence.
For now, Wegovy should not be taken solely to prevent breast cancer. The FDA has not approved it for that purpose. Women should continue recommended mammograms, know their family history, maintain a healthy weight when possible and discuss personal risk factors with a healthcare professional.
The research is promising — but “possible protection” is not yet the same as proven prevention.